YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Effect of Ophthalmic Fluoroquinolones on Bacterial Conjunctivitis: Systematic Review

세균성결막염에 대한 안과용 플루오로퀴놀론계 항균제의 효과: 체계적문헌고찰

  • Received : 2010.10.09
  • Accepted : 2010.12.01
  • Published : 2011.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

This systematic review was conducted to assess the clinical effect of ocular fluoroquinolones used for the treatment of bacterial conjunctivitis. A literature search for randomized controlled clinical trials registered up to January 2010 based on PubMed database, using the following search terms: conjunctivitis and fluoroquinolones (besifloxacin, moxifloxacin, gatifloxacin, levofloxacin, lomefloxacin, ciprofloxacin and ofloxacin) were performed. Pooled data on the clinical resolution and bacterial eradication rates derived from selected 16 studies were reported as the relative risk (RR) and 95% confidence interval (95% CI) compared with placebo. Early clinical resolution and microbiological eradication rates in placebo were 28% and 62% respectively. Fluoroquinolones were significantly effective comparing to placebo: early RR 1.94 (95% CI 1.60~2.34) and late RR 1.30 (1.19~1.43) in clinical resolution rates, and early RR 1.75 (1.58~1.94) and late RR 1.28 (1.18~1.39) in microbiological eradication rates. Besifloxacin, ciprofloaxain and moxifloxacin in clinical resolution, and besifloxacin and levofloxacin in microbiological eradication showed higher RRs than pooled overall fluoroquinolones' RRs. New quinolones had higher antibacterial potencies for all pathogens isolated from bacterial conjunctivitis and resistant isolates than old generation quinolones. In conclusion, ocular 7 fluoroquinolones were all effective than placebo for bacterial conjunctivitis and there were differences between quinolones in early and late clinical resolutions and microbiological eradications, and no differences in safety comparing to placebo.

Keywords

References

  1. Hovding, G. : Acute bacterial conjunctivitis. Acta Ophthalmol. 86, 5 (2008).
  2. Granet, D. B., Dorfman, M. and Stroman, D. : A multicenter comparison of polymyxin B sulfate/trimethoprim ophthalmic solution and moxifloxacin in the speed of clinical efficacy for the treatment of bacterial conjunctivitis. J. Pediatr. Ophthalmol. Strabismus 45, 340 (2008). https://doi.org/10.3928/01913913-20081101-07
  3. 건강보험심사평가원 : 2008년 진료비통계지표. Available at http://www.hira.or.kr/common/dummy. jsp?pgmid=HIRAF010303000000 (Accessed Feb 11, 2010).
  4. 건강보험심사평가원 : 병원.질병정보. 다빈도질병. Available at http://www.hira.or.kr/rdd_disease.do?method=listHifreqdiseinfo&pgmid=HIRAA020200000000 (Accessed Feb 11, 2010).
  5. Weiss, A., Brinser, J. H. and Nazar-Stewart, V. : Acute conjunctivitis in children. J. Pediatr. 122, 10 (1993). https://doi.org/10.1016/S0022-3476(05)83479-1
  6. Tepedino, M. E., Heller, W. H., Usner, D. W., Brunner, L. S., Morris, T. W., Haas, W., Paterno, M. R. and Comstock, T. L. : Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin. 25, 1159 (2009). https://doi.org/10.1185/03007990902837919
  7. Lichtenstein, S. J., Wagner, R. S., Jamison, T., Bell, B. and Stroman, D. W. : Speed of bacterial kill with a fluoroquinolone compared with nonfluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv. Ther. 24, 1098 (2007). https://doi.org/10.1007/BF02877716
  8. Sheikh, A. and Hurwitz, B. : Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2, CD001211 (2006).
  9. McDonald, M. B., Protzko, E. E., Brunner, L. S., Morris, T. W., Haas, W., Paterno, M. R., Comstock, T. L. and Usner, D. W. : Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology. 116, 1615 (2009). https://doi.org/10.1016/j.ophtha.2009.05.014
  10. Egger, S. F., Ruckhofer, J. and Alzner, E. : In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic Res. 33, 117 (2001). https://doi.org/10.1159/000055655
  11. Kaliamurthy, J., Nelson Jesudasan, C. A. and Geraldine, P. : Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics. Ophthalmic Res. 37, 117 (2005).
  12. Ward, K. W., Lepage, J. F. and Driot, J. Y. L. : Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL- 303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J. Ocul. Pharmacal. Ther. 23, 243 (2007). https://doi.org/10.1089/jop.2006.0137
  13. Hwang, D. G. : Fluoroquinolone resistance in ophthalmology and the potential role for new ophthalmic fluoroquinolones. Surv. Ophthalmol. 49, S79 (2004). https://doi.org/10.1016/j.survophthal.2004.01.004
  14. 식품의약품안전청 : 의약품 등 정보. Available at http://ezdrug.kfda.go.kr/kfda2 (Accessed October 23, 2009).
  15. Karpecki, P., Depaolis, M., Hunter, J. A., White, E. M., Rigel, L., Brunner, L. S., Usner, D. W., Paterno, M. R. and Comstock, T. L. : Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin. Ther. 31, 514 (2009). https://doi.org/10.1016/j.clinthera.2009.03.010
  16. Szaflik, J., Szaflik, J. P. and Kaminska, A. : Levofloxacin bacterial conjunctivitis dosage study group. Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis. Eur. J. Ophthalmol. 19, 1 (2009).
  17. Yee, R. W., Tepedino, M., Bernstein, P., Jensen, H., Schiffman, R. and Whitcup, S. M. : Gatifloxacin BID/QID study group: A randomized, investigator- masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment BID versus QID for the treatment of acute bacterial conjunctivitis of acute bacterial conjunctivitis. Curr. Med. Res. Opin. 21, 425 (2005). https://doi.org/10.1185/030079905X30699
  18. Hwang, D. G., Schanzlin, D. J., Rotberg, M. H., Foulks, G. and Raizman, M. B. : Levofloxacin bacterial conjunctivitis placecontrolled study group: A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br. J. Ophthalmol. 87, 1004 (2003). https://doi.org/10.1136/bjo.87.8.1004
  19. Schwab, I. R., Friedlaender, M., McCulley, J., Lichtenstein, S. J. and Moran, C. T. : Levofloxacin bacterial conjunctivitis active control study group: A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 110, 457 (2003). https://doi.org/10.1016/S0161-6420(02)01894-8
  20. Tabbara, K. F., El-Sheikh, H. F., Islam, S. M. and Hammouda, E. : Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%. Eur. J. Ophthalmol. 9, 269 (1999). https://doi.org/10.1177/112067219900900403
  21. Gross, R. D., Hoffman, R. O. and Lindsay, R. N. : A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin. Pediatr. (Phila). 36, 435 (1997). https://doi.org/10.1177/000992289703600801
  22. Adenis, J. P., Brasseur, G., Demailly, P., Malet, F., Verin, P., Saint-Blancat, P., Retout, A., Oll, P. and Colin, J. : Comparative evaluation of efficacy and safety of ciprofloxacin and norfloxacin ophthalmic solutions. Eur. J. Ophthalmol. 6, 287 (1996).
  23. Adenis, J. P., Colin, J., Verin, P., Saint-Blancat, P. and Malet, F. : Ciprofloxacin ophthalmic solution versus rifamycin ophthalmic solution for the treatment of conjunctivitis and blepharitis. Eur. J. Ophthalmol. 5, 82 (1995).
  24. Gwon, A. : Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group. Br. J. Ophthalmol. 76, 714 (1992). https://doi.org/10.1136/bjo.76.12.714
  25. Gwon, A. : Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. Arch Ophthalmol. 110, 1234 (1992). https://doi.org/10.1001/archopht.1992.01080210052022
  26. Bron, A. J., Leber, G., Rizk, S. N., Baig, H., Elkington, A. R., Kirkby, G. R., Neoh, C., Harden, A. and Leong, T. : Ofloxacin compared with chloramphenicol in the management of external ocular infection. Br. J. Ophthalmol. 75, 675 (1991). https://doi.org/10.1136/bjo.75.11.675
  27. Leibowitz, H. M. : Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am. J. Ophthalmol. 112, 29S (1991).
  28. Schlech, B. A. and Blondeau, J. : Future of ophthalmic antiinfective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv. Ophthalmol. 50, S64 (2005). https://doi.org/10.1016/j.survophthal.2005.05.005
  29. Bertino, J. S. and Zhang, J. : Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. Expert Opinion on Pharmacotherapy 10, 2545 (2009). https://doi.org/10.1517/14656560903213413